Compare SMG & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMG | CLDX |
|---|---|---|
| Founded | 1868 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.0B |
| IPO Year | 2012 | 1995 |
| Metric | SMG | CLDX |
|---|---|---|
| Price | $49.67 | $29.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 15 |
| Target Price | ★ $74.17 | $63.07 |
| AVG Volume (30 Days) | 1.1M | ★ 2.0M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | ★ 5.24% | N/A |
| EPS Growth | ★ 504.92 | N/A |
| EPS | ★ 3.82 | N/A |
| Revenue | ★ $3,016,500,000.00 | $12,743,000.00 |
| Revenue This Year | N/A | $19.74 |
| Revenue Next Year | $2.27 | $438.11 |
| P/E Ratio | $13.20 | ★ N/A |
| Revenue Growth | 6.17 | ★ 87.78 |
| 52 Week Low | $47.90 | $22.10 |
| 52 Week High | $75.34 | $45.14 |
| Indicator | SMG | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 36.43 | 30.57 |
| Support Level | $47.90 | $28.82 |
| Resistance Level | $63.66 | $31.80 |
| Average True Range (ATR) | 1.62 | 1.90 |
| MACD | 0.29 | -0.20 |
| Stochastic Oscillator | 32.51 | 12.44 |
Scotts Miracle-Gro is the largest purveyor of home lawn and gardening products in the US. The company sells a broad range of lawncare products, including grass seed, fertilizer, and lawn-related weed, animal, and disease control. US consumer typically generates the vast majority of companywide revenue and profits. Its lawncare and gardening products are well-recognized brands in the US, including Scotts, Miracle-Gro, Roundup, Ortho, and Tomcat. Over half of revenue typically comes from Home Depot and Lowe's, as Scotts' products are featured at both home improvement retailers.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.